Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

B-cell Lymphoma

Lymphosarcoma

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Lenalidomide

Immunologic Factors

Angiogenesis Inhibitors

Growth Inhibitors

Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP

Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.

Lenalidomide and R-CHOP

Hervé TILLY, Prof

The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).

The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with B-cell lymphoma.

Lenalidomide and R-CHOP in B-cell Lymphoma

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

Lymphoma Study Association

Michel MEIGNAN, Prof

Jehan DUPUIS, MD

The purpose of the study is to assess in a prospective series of patients with high tumor burden follicular lymphoma treated with R-CHOP, the predictive value of \[18F\]-FDG PET performed over (after 4 treatments), and at the end of the first-line treatment on progression-free survival at 2 years.

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Lenalidomide and R-CHOP in B-cell Lymphoma	NCT00901615	Lymphoma, Large... Follicular Lymp... Mantle Cell Lym... Marginal Zone L...	Lenalidomide an...	18 Years - 70 Years	Lymphoma Study Association
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma	NCT00915096	Lymphoma, Folli...		18 Years - 80 Years	Lymphoma Study Association
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma	NCT00915096	Lymphoma, Folli...		18 Years - 80 Years	Lymphoma Study Association
Lenalidomide and R-CHOP in B-cell Lymphoma	NCT00901615	Lymphoma, Large... Follicular Lymp... Mantle Cell Lym... Marginal Zone L...	Lenalidomide an...	18 Years - 70 Years	Lymphoma Study Association

Spots Global Cancer Trial Database for gela

Every month we try and update this database with for gela cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for gela

Every month we try and update this database with for gela cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for gela cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.